Literature DB >> 28691508

Substantial improvement of primary cardiovascular prevention by a systematic score-based multimodal approach: A randomized trial: The PreFord-Study.

Detlef Bernd Gysan1, Stefanie Millentrup2, Christian Albus3, Birna Bjarnason-Wehrens4, Joachim Latsch4, Helmut Gohlke5,6, Gerd Herold7, Karl Wegscheider8, Christian Heming4, Melchior Seyfarth1, Hans-Georg Predel4.   

Abstract

Trial design Prospective randomized multicentre interventional study. Methods Individual cardiovascular risk assessment in Ford Company, Germany employees ( n = 4.196), using the European Society of Cardiology-Systematic Coronary Risk Evaluation (ESC-SCORE) for classification into three risk groups. Subjects assigned to ESC high-risk group (ESC-SCORE ≥ 5%), without a history of cardiovascular disease were eligible for randomization to a multimodal 15-week intervention programme (INT) or to usual care and followed up for 36 months. Objectives Evaluation of the long-term effects of a risk-adjusted multimodal intervention in high-risk subjects. Primary endpoint: reduction of ESC-SCORE in INT versus usual care. Secondary endpoints: composite of fatal and non-fatal cardiovascular events and time to first cardiovascular event. STATISTICAL ANALYSIS: intention-to-treat and per-protocol analysis. Results Four hundred and forty-seven subjects were randomized to INT ( n = 224) or to usual care ( n = 223). After 36 months ESC-SCORE development favouring INT was observed (INT: 8.70% to 10.03% vs. usual care: 8.49% to 12.09%; p = 0.005; net difference: 18.50%). Moreover, a significant reduction in the composite cardiovascular events was observed: (INT: n = 11 vs. usual care: n = 27). Hazard ratio of intervention versus control was 0.51 (95% confidence interval 0.25-1.03; p = 0.062) in the intention-to-treat analysis and 0.41 (95% confidence interval 0.18-0.90; p = 0.026) in the per-protocol analysis, respectively. No intervention-related adverse events or side-effects were observed. Conclusions Our results demonstrate the efficiency of identifying cardiovascular high-risk subjects by the ESC-SCORE in order to enrol them to a risk adjusted primary prevention programme. This strategy resulted in a significant improvement of ESC-SCORE, as well as a reduction in predefined cardiovascular endpoints in the INT within 36 months. (ISRCTN 23536103.).

Entities:  

Keywords:  ESC-SCORE; Primary prevention; cardiovascular diseases; risk stratification; risk-adjusted multimodal intervention

Mesh:

Year:  2017        PMID: 28691508     DOI: 10.1177/2047487317718081

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  4 in total

Review 1.  Risk scoring for the primary prevention of cardiovascular disease.

Authors:  Kunal N Karmali; Stephen D Persell; Pablo Perel; Donald M Lloyd-Jones; Mark A Berendsen; Mark D Huffman
Journal:  Cochrane Database Syst Rev       Date:  2017-03-14

2.  Results of a prospective cardiovascular disease prevention program.

Authors:  Arn Eliasson; Mariam Kashani; Marina Vernalis
Journal:  Prev Med Rep       Date:  2021-03-12

3.  Effects of a comprehensive lifestyle intervention on cardiovascular health: the TANSNIP-PESA trial.

Authors:  Ines Garcia-Lunar; Hidde P van der Ploeg; Juan Miguel Fernández Alvira; Femke van Nassau; Jose Maria Castellano Vázquez; Allard J van der Beek; Xavier Rossello; Antonio Fernández-Ortiz; Jennifer Coffeng; Johanna M van Dongen; Jose Maria Mendiguren; Borja Ibáñez; Willem van Mechelen; Valentin Fuster
Journal:  Eur Heart J       Date:  2022-10-11       Impact factor: 35.855

4.  Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemia.

Authors:  Bernhard Rauch
Journal:  Eur J Prev Cardiol       Date:  2020-04-17       Impact factor: 7.804

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.